A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFRmutated, non–small cell lung cancer

Recent reports suggested combining ramucirumab with epidermal growth factor receptor (EGFR)- tyrosine kinase inhibitors (TKIs) to overcome EGFR resistance in non–small cell lung cancer (NSCLC).